Abstract: Berzosertib (also known as VE-822, VX-970, or M6620) is a first-in-class, intravenously administered, highly potent and selective inhibitor of the Ataxia telangiectasia and Rad3-related (ATR) kinase. Originally developed to exploit the synthetic lethality of tumors with high replication stress and DNA damage response (DDR) defects, berzosertib has demonstrated significant clinical potential both as a monotherapy and in combination with DNA-damaging chemotherapies and radiotherapy. Recently, a novel research direction has emerged highlighting the profound impact of ATR inhibition on the tumor microenvironment (TME). By promoting genomic instability and the accumulation of cytosolic DNA, berzosertib activates the cGAS-STING signaling pathway, driving type-I interferon responses and enhancing the infiltration of cytotoxic T cells into the TME. Furthermore, berzosertib has been shown to modulate immune checkpoint expression, such as downregulating PD-L1 and mitigating regulatory T cell infiltration. This comprehensive review synthesizes current literature on berzosertib, focusing on its pharmacological profile, molecular mechanisms—particularly its intersection with tumor immunology—and its future prospects in combination with immunotherapy.
1. Introduction
Genomic instability and replication stress (RepStress) are fundamental hallmarks of cancer. The DNA damage response (DDR) network is crucial for maintaining genomic integrity, with the Ataxia telangiectasia and Rad3-related (ATR) kinase serving as a master regulator of the cellular response to replication stress [2]. ATR is activated by single-stranded DNA (ssDNA) coated with replication protein A (RPA), which typically arises at stalled replication forks or resected DNA double-strand breaks (DSBs) [4]. Because many cancers harbor defects in other DDR pathways (such as ATM or p53 mutations) and exhibit high endogenous replication stress due to oncogene activation, they become heavily reliant on the ATR pathway for survival [2][4].
Berzosertib (VE-822, VX-970, M6620), developed by EMD Serono/Merck, is a first-in-class ATR inhibitor that has entered advanced clinical development [2][4]. While its initial clinical rationale was based on synthetic lethality and radio/chemosensitization, recent preclinical and clinical evidence has unveiled its capacity to profoundly alter the tumor microenvironment (TME). By bridging DNA damage with innate immune sensing, berzosertib is now at the forefront of investigations combining DDR inhibitors with immune checkpoint blockade [3][4].
2. Pharmacological Activity
Berzosertib is administered intravenously and exhibits a favorable and predictable pharmacokinetic (PK) profile. It demonstrates moderate to high clearance (approximately 60 L/h), a high volume of distribution (Vd; ~1250 L), and a terminal half-life (t1/2) of approximately 17 hours [1]. The pharmacokinetics of berzosertib are dose-linear across a wide range (18–480 mg/m2) and remain unchanged upon coadministration with combination drugs. Population PK analyses indicate that berzosertib PK is not significantly sensitive to ethnic factors, enabling seamless global clinical development [1].
Clinically, berzosertib has shown durable single-agent antitumor activity, particularly in patients with advanced cancers harboring ATM aberrations [2]. In combination therapies, it has demonstrated remarkable efficacy. For instance, in a Phase II trial for platinum-resistant high-grade serous ovarian cancer, the combination of berzosertib and gemcitabine significantly prolonged progression-free survival (PFS) compared to gemcitabine alone (22.9 weeks vs. 14.7 weeks) while reducing the proportion of severe adverse reactions [3]. It has also yielded durable regressions in chemotherapy-resistant small cell neuroendocrine cancers (SCNCs) when combined with topotecan, achieving an objective response rate (ORR) of 36% in relapsed small cell lung cancer (SCLC) [1][2]. Furthermore, berzosertib exhibits good blood-brain barrier (BBB) penetration in preclinical models, showing a radiosensitizing effect in non-small cell lung cancer (NSCLC) brain metastases [3].
3. Molecular Mechanism of Action
The primary mechanism of action of berzosertib involves the potent and selective inhibition of the ATR kinase. Under normal conditions, ATR phosphorylates and activates checkpoint kinase 1 (CHK1), which subsequently prevents genomic instability by regulating origin firing, ensuring a sufficient deoxynucleotide (dNTP) pool, stabilizing replication forks, and arresting the cell cycle at the G2-M transition to allow for DNA repair [4]. By inhibiting ATR, berzosertib abrogates these cell cycle checkpoints, forcing cancer cells with high replication stress to undergo premature mitosis and subsequent mitotic catastrophe (synthetic lethality) [2][4].
Modulation of the Tumor Microenvironment and Immunotherapy:
Beyond direct cytotoxicity, berzosertib plays a critical role in modulating the TME. The inhibition of ATR exacerbates genomic instability, leading to the accumulation of chromosome fragments and double-strand breaks in the cytoplasm. These cytosolic DNA fragments are recognized by the DNA sensor cyclic GMP-AMP synthase (cGAS), which synthesizes cGAMP to activate the stimulator of interferon genes (STING) pathway [3]. STING activation recruits Tank-binding kinase 1 (TBK1) to phosphorylate interferon regulatory factor 3 (IRF3), promoting the transcription of type-I interferons (IFNs) [3]. This type-I IFN response upregulates chemokines such as CXCL10 and CCL5, which effectively drive the infiltration and activation of dendritic cells and effector CD8+ T cells into the tumor bed [3].
Additionally, preclinical evidence indicates that ATR inhibition by berzosertib can downregulate programmed death-ligand 1 (PD-L1) expression on cancer cell surfaces and mitigate the tumor infiltration of immunosuppressive regulatory T cells following radiation or cisplatin treatment [4]. Conversely, the cGAS-STING pathway activation can sometimes lead to a compensatory increase in PD-L1 expression [3]. Together, these mechanisms provide a strong mechanistic rationale for combining berzosertib with immune checkpoint inhibitors to overcome immune evasion and turn "cold" tumors into immunologically "hot" tumors.
4. Structure-Activity Relationship (SAR)
Berzosertib targets ATR, which is a member of the phosphoinositide 3-kinase-related protein kinase (PIKK) family. The PIKK family members (which also include ATM, DNA-PK, and mTOR) share a highly conserved kinase domain that is structurally similar to that of the phosphoinositide 3-kinases (PI3Ks) [3]. Because of this structural homology in the ATP-binding cleft, chemical inhibitors of PI3K and PIKK kinases often share similar structural motifs, such as the morpholine ring, which is critical for binding affinity [3]. Despite these similarities, berzosertib was developed through rigorous chemical optimization to achieve high selectivity for ATR over other PIKK family members, minimizing off-target effects while maximizing the disruption of the ATR-CHK1 signaling axis [3].
5. Current Limitations
Despite its promising clinical profile, the development and application of berzosertib face several limitations:
1. Route of Administration: Unlike newer ATR inhibitors such as ceralasertib and elimusertib, which are orally bioavailable, berzosertib requires intravenous administration. This can be less convenient for patients, requiring clinical visits for infusions [2].
2. Toxicity to Normal Tissues: Because ATR is essential for the survival of replicating cells, berzosertib can induce dose-limiting toxicities in normal proliferating tissues. Common grade 3/4 adverse events observed in clinical trials include hematological toxicities such as neutropenia, thrombocytopenia, leukopenia, and anemia [4].
3. Overlapping Toxicities in Combinations: When combined with other DNA-damaging agents (e.g., PARP inhibitors or cytotoxic chemotherapies), overlapping toxicities—particularly myelosuppression—can limit the tolerability of the regimen, necessitating careful dose reductions or intermittent dosing schedules [3][4].
6. Future Perspectives
The future clinical development of berzosertib is highly focused on precision oncology and rational combination strategies:
1. Immunotherapy Combinations: Given its ability to activate the STING pathway and modulate PD-L1, combining berzosertib with immune checkpoint inhibitors (anti-PD-1/PD-L1) represents a major frontier. Trimodality therapies—combining an ATR inhibitor, an immune checkpoint inhibitor, and localized ionizing radiation—are currently being explored to maximize systemic anti-tumor immune responses [4].
2. Biomarker-Driven Patient Selection: Identifying patients most likely to respond is critical. Tumors with ATM deficiency (which creates a synthetic lethal reliance on ATR) are prime targets [2]. Additionally, the expression of Schlafen 11 (SLFN11) and transcriptomic "RepStress" signatures are being validated as predictive biomarkers to identify tumors with high endogenous replication stress that will be exquisitely sensitive to ATR inhibition [2].
3. Optimized Dosing Schedules: To mitigate toxicity to normal tissues, novel scheduling approaches are being investigated. For example, a "Gap-schedule" protocol involves administering the ATR inhibitor during the interval between doses of tumor-targeted DNA damaging agents (like antibody-drug conjugates or TOP1 inhibitors), allowing normal tissues to clear the chemotherapy while the tumor remains loaded, thereby widening the therapeutic window [2].
